Martini Jeffrey S

Chief Scientific Officer

Martini Jeffrey S has filed 1 SEC Form 4 filing (16 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.

On the most recent filing, Martini Jeffrey S is listed as Chief Scientific Officer at PALVELLA THERAPEUTICS, INC. Inside the rolling window, Martini Jeffrey S reported no open-market purchases and 2 open-market sales totaling $2.1M in PVLA. The largest disclosed transaction in the window is a sale of 6,250 PVLA shares on Nov 10, 2026, worth $1.0M.

Companies traded

Other insiders at PVLA

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$2.1M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
PVLASale$1.0MNov 12SEC ↗
PVLASale$1.0MNov 12SEC ↗
Showing 1–2 of 2
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Martini Jeffrey S made?

Martini Jeffrey S has filed 1 SEC Form 4 filing (16 transaction rows) across 1 company since 2026.

Which companies does Martini Jeffrey S trade?

Martini Jeffrey S has filed SEC Form 4 disclosures for 1 company, including PVLA.

When was Martini Jeffrey S's most recent SEC Form 4 filing?

Martini Jeffrey S's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.

What is Martini Jeffrey S's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Martini Jeffrey S is listed as Chief Scientific Officer.

What is Martini Jeffrey S's total buy and sell value in the current window?

Inside the rolling retention window, Martini Jeffrey S bought $0 and sold $2.1M based on SEC Form 4 filings.

What was Martini Jeffrey S's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 6,250 PVLA shares on 2026-11-10, worth $1.0M, per SEC Form 4 filings.